Progress in oncology features significant strides in targeted therapies and precision diagnostics. Companies such as 4D Molecular Therapeutics demonstrate durable efficacy in diabetic macular edema gene therapy, reducing injection frequency. NeoGenomics expands liquid biopsy assays for comprehensive cancer genomic profiling, facilitating treatment selection. Additionally, single-cell transcriptomics and multiomics approaches illuminate tumor-immune interactions, enabling refined therapeutic targeting. These advances reflect a growing emphasis on personalized oncology care through molecular and cellular insights.